Effects of Evolocumab Versus Placebo Added to Standard Lipid-lowering Therapy on Fasting and Post Fat Load Lipids in Patients With Familial Dysbetalipoproteinemia

PHASE4UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2019

Primary Completion Date

January 31, 2021

Study Completion Date

March 31, 2021

Conditions
Familial DysbetalipoproteinemiaHyperlipoproteinemia Type III
Interventions
DRUG

Evolocumab Auto-Injector [Repatha]

Evolocumab 140 mg every 2 weeks for 12 weeks

DRUG

Placebos

Placebo subcutaneous injection every 2 weeks for 12 weeks

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

collaborator

Erasmus Medical Center

OTHER

collaborator

University Medical Center Nijmegen

OTHER

lead

UMC Utrecht

OTHER

NCT03811223 - Effects of Evolocumab Versus Placebo Added to Standard Lipid-lowering Therapy on Fasting and Post Fat Load Lipids in Patients With Familial Dysbetalipoproteinemia | Biotech Hunter | Biotech Hunter